Immunoaugmentative therapy. A primer on the perils of unproved treatments

JAMA
|January 24, 1986
PubMed

Immunoaugmentative therapy is an unproved cancer treatment that until recently was offered to patients by zoologist Lawrence Burton, PhD, at a facility in Freeport, Bahamas. The therapy consists of serum measurements of certain "immune deficiencies" and purportedly restores immune function by injection of products variously derived from tumor tissue and blood from individuals with cancer and healthy volunteers. Immunoaugmentative therapy represents a potentially serious public health risk, since it is capable of transmitting hepatitis B and the presumed etiologic agent for the acquired immunodeficiency syndrome. Physicians and health officials who learn of patients receiving this therapy are advised that its efficacy remains unproved and that the risk of receiving contaminated blood products is considerable.

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.